We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Patent Board Denies Review Of Patents Related To Natalizumab

(October 20, 2016, 12:28 PM EDT) -- ALEXANDRIA, Va. — Three petitions for inter partes review (IPR) of patents covering the immunosuppressant drug natalizumab — marketed under the brand name “Tysabri” — were denied Oct. 17 by the Patent Trial and Appeal Board (Swiss Pharma International AG v. Biogen IDEC, No. IPR2016-00912, PTAB).

(Decision re: ‘321 patent available.  Document #16-161107-007Z.)

According to the board, contrary to assertions raised by petitioner Swiss Pharma International AG, it is unlikely that claims 1-4 of U.S. patent No. 8,349,321, claims 1, 3-7 and 9-12 of U.S. patent...
To view the full article, register now.